Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Leflunomide · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Leflunomide 20 mg Tablets (Geneva Pharmaceutical) |
| 2 | ACTIVE_COMPARATOR | Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.) |
| Name | Type | Description |
|---|---|---|
| Leflunomide 20 mg Tablets (Geneva Pharmaceutical) | DRUG | - |
| Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Top 20 of 28 competitors
Leflunomide is a small molecule being developed for the treatment of rheumatoid arthritis. It is also being studied in psoriatic arthritis. The drug is currently in Phase 1 clinical development and is being developed by Novartis AG.
Leflunomide is being developed by Novartis AG, which is publicly traded under the ticker symbol NVS. The drug is a small molecule in the immunology therapeutic area, currently in Phase 1 clinical development for rheumatoid arthritis.
Leflunomide is in Phase 1 clinical development. It is an investigational drug being studied for rheumatoid arthritis. The drug has completed one Phase 1 clinical trial, and it is not yet approved by regulatory authorities.
Leflunomide has one completed clinical trial registered as NCT00946686. This Phase 1 study, titled "To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions," enrolled 52 participants and was an active-controlled, randomized trial.
Leflunomide is the generic name for the drug also known as Arava. It is being developed by Novartis AG for rheumatoid arthritis. The drug is currently in Phase 1 clinical development and is not yet approved.